In our hospital (CHR Metz-Thionville), we observe more infusion reactions with cetuximab (Erbitux®) than the infusion reactions’ rate described in the scientific literature (5.1% of severe allergic reactions versus 1% in the data of the pharmaceutical firm).
Therefore, in collaboration with oncologists, we would like compare our conditions of preparation and administration with practices of other healthcare institutions.
The arrival of an allergist at the same time in our hospital leads to propose testing allergic reactions and we wonder if you practice similar tests in your healthcare center.
Therefore, would you accept to answer this on-line survey (estimated-time above 20 minutes).
The results of the questionnaires will be analyzed by an hospital junior pharmacist. The participants will be informed about the results.
We thank you for your cooperation.
Véronique Noirez Anne-Laure Kienlin
Hospital practitioner Hospital junior pharmacist
CHR Metz-Thionville Hospital of Mercy Metz